2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claims
2022
Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients
Friedman DJ, Qin L, Parzynski C, Heist EK, Russo AM, Ranasinghe I, Zeitler EP, Minges KE, Akar JG, Freeman JV, Curtis JP, Al-Khatib SM. Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. Journal Of The American College Of Cardiology 2022, 79: 1050-1059. PMID: 35300816, DOI: 10.1016/j.jacc.2021.12.033.Peer-Reviewed Original ResearchConceptsOlder patientsCause readmissionS-ICDNational Cardiovascular Data Registry ICD RegistryDevice removalTransvenous implantable cardioverter defibrillatorTV-ICD patientsRisk of deathS-ICD patientsService Medicare beneficiariesAnderson-Gill modelsImplantable cardioverter defibrillatorRepresentative national cohortCompeting-risks modelTV-ICDCardiovascular readmissionCause mortalityICD implantationYounger patientsICD RegistryNonfatal outcomesTransvenous ICDAtrial fibrillationNational cohortCardioverter defibrillator
2021
Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry)
Daimee UA, Aslam F, Parzynski CS, Desai NR, Curtis JP. Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry). The American Journal Of Cardiology 2021, 155: 64-71. PMID: 34315569, DOI: 10.1016/j.amjcard.2021.06.020.Peer-Reviewed Original ResearchConceptsPrimary prevention ICD implantationRisk of mortalityICD implantationHeart failureICD RegistryMortality riskNational Cardiovascular Data Registry ICD RegistryPivotal randomized clinical trialsHospital adverse eventsSevere heart failureRecent myocardial infarctionCause hospital readmissionRandomized clinical trialsSimilar mortality riskLongitudinal outcomesImplantable cardioverter defibrillatorGreater mortality riskCause hospitalizationCause mortalityCoronary revascularizationAdverse eventsHospital readmissionICD recipientsDevice implantationPrimary prevention
2020
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis
Weissler EH, Annapureddy A, Wang Y, Secemsky EA, Shishehbor MH, Mena-Hurtado C, Jelani QU, Aronow HD, Tsai TT, Patel MR, Curtis JP, Jones WS. Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal 2020, 233: 59-67. PMID: 33321119, PMCID: PMC8078180, DOI: 10.1016/j.ahj.2020.12.004.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsPCD usePaclitaxel-coated devicesChronic total occlusionSignificant differencesCause mortalityAnalytic cohortFemoropopliteal lesionsOverall cohortPopliteal arteryPrimary outcomeRegistry analysisTotal occlusionUnadjusted ratesFemoropopliteal stenosesInverse probability weightingVascular interventionsAmerican CollegePatientsPractice settingsMortalityReal-world useClaim outcomesDevice useOutcomesSurvival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016038. PMID: 32867553, PMCID: PMC7726970, DOI: 10.1161/jaha.120.016038.Peer-Reviewed Original ResearchConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationNonischemic cardiomyopathyCardiac amyloidosisDiabetes mellitusCerebrovascular diseaseVentricular tachycardiaMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesCox proportional hazards modelPropensity-matched cohortOutcomes of patientsHazards regression modelsProportional hazards modelCause mortalityICD implantationRenal functionMultivariable analysisConclusions MortalityRisk factorsRegistry dataAmyloid cardiomyopathyHigh riskComparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes
Hyman MC, Bao H, Curtis JP, Minges K, Schaller RD, Birgersdotter-Green U, Marchlinski FE, Hsu JC. Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes. Heart Rhythm 2020, 17: 1878-1886. PMID: 32497762, DOI: 10.1016/j.hrthm.2020.05.032.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapyCRT-eligible patientsCRT upgradeResynchronization therapyClinical outcomesNational Cardiovascular Data Registry ICD RegistryGenerator replacementPeriprocedural complication rateLeft ventricular leadSubpopulation of patientsLong-term outcomesICD generator replacementHierarchical logistic regression modelsLogistic regression modelsSecondary endpointsCause mortalityPrimary endpointComplication rateICD RegistryProcedural complicationsMedical managementICD populationNational registryVentricular leadClaims data
2019
Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population
Dreyer RP, Tavella R, Curtis JP, Wang Y, Pauspathy S, Messenger J, Rumsfeld JS, Maddox TM, Krumholz HM, Spertus JA, Beltrame JF. Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population. European Heart Journal 2019, 41: 870-878. PMID: 31222249, PMCID: PMC7778433, DOI: 10.1093/eurheartj/ehz403.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsAcute myocardial infarctionHeart failureMyocardial infarctionCoronary angiographyComponents of MACENational Cardiovascular Data Registry CathPCI RegistryNon-obstructive coronary arteriesObstructive coronary artery diseaseAdverse cardiac eventsMajor adverse eventsObservational cohort studyObstructive coronary diseasePrognosis of patientsCoronary artery diseaseMACE componentsMINOCA patientsAdjusted riskCause mortalityPrimary endpointSecondary endpointsAdverse eventsCardiac eventsCathPCI RegistryCohort study
2017
Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry
Kipp R, Hsu JC, Freeman J, Curtis J, Bao H, Hoffmayer KS. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm 2017, 15: 847-854. PMID: 28987459, DOI: 10.1016/j.hrthm.2017.09.043.Peer-Reviewed Original ResearchConceptsCause mortalityMedicare beneficiariesICD implantationProcedural complicationsHospital characteristicsMultivariable Cox proportional hazards regression analysisNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression analysisFirst-time ICD recipientsImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistryProportional hazards regression analysisKaplan-Meier survival analysisLong-term morbidityPredictors of mortalityCardioverter-defibrillator implantationOccurrence of complicationsRetrospective registry studyAcute procedural complicationsHazards regression analysisLong-term outcomesRisk of mortalityMortality 3 yearsIndex hospitalizationRegistry studyCarotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014
Lichtman JH, Jones MR, Leifheit EC, Sheffet AJ, Howard G, Lal BK, Howard VJ, Wang Y, Curtis J, Brott TG. Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014. JAMA 2017, 318: 1035-1046. PMID: 28975306, PMCID: PMC5818799, DOI: 10.1001/jama.2017.12882.Peer-Reviewed Original ResearchConceptsVascular risk factorsCarotid endarterectomyCarotid arteryHospital mortalityCause mortalityRevascularization ratesIschemic strokeMyocardial infarctionRisk factorsMedicare beneficiariesSerial cross-sectional analysisUnderwent carotid arteryNumber of patientsUS national trendsService Medicare beneficiariesCross-sectional analysisSymptomatic patientsSymptomatic statusUnique patientsCarotid stenosisEndarterectomyMedicare inpatientMAIN OUTCOMEMedicare feePatientsSeattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O’Conner C, Levy WC. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. Journal Of The American College Of Cardiology 2017, 69: 2606-2618. PMID: 28545633, PMCID: PMC5502749, DOI: 10.1016/j.jacc.2017.03.568.Peer-Reviewed Original ResearchConceptsSeattle Heart Failure ModelSeattle Proportional Risk ModelNational Cardiovascular Data RegistryPrimary prevention ICDsHeart failureSudden deathCause mortalitySurvival benefitMultivariable Cox proportional hazards regressionCox proportional hazards regressionProportional riskProportional hazards regressionRecent clinical trialsHeart failure modelProportional risk modelControl patientsOverall survivalVentricular arrhythmiasHazards regressionICD benefitClinical trialsCardioverter defibrillatorLarge cohortHigh riskData registry
2015
Use of Remote Monitoring Is Associated With Lower Risk of Adverse Outcomes Among Patients With Implanted Cardiac Defibrillators
Akar JG, Bao H, Jones PW, Wang Y, Varosy PD, Masoudi FA, Stein KM, Saxon LA, Normand SL, Curtis JP. Use of Remote Monitoring Is Associated With Lower Risk of Adverse Outcomes Among Patients With Implanted Cardiac Defibrillators. Circulation Arrhythmia And Electrophysiology 2015, 8: 1173-1180. PMID: 26092577, DOI: 10.1161/circep.114.003030.Peer-Reviewed Original ResearchConceptsImplantable cardioverter defibrillatorInitial implantable cardioverter defibrillatorCause mortalityLower riskAdverse outcomesNational Cardiovascular Data Registry ICD RegistryRemote patient monitoringSocial Security Death Master FileCause rehospitalization rateRisk of rehospitalizationImplanted cardiac defibrillatorsDeath Master FileCardiomyopathy pathogenesisCause rehospitalizationICD RegistryRehospitalization ratesMultivariable analysisStudy cohortVital statusService patientsCardioverter defibrillatorCox modelMedicare populationMedicare feePatients
2014
Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women
Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, Sanders GD, Al-Khatib SM. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC Heart Failure 2014, 3: 159-167. PMID: 25543969, PMCID: PMC4461749, DOI: 10.1016/j.jchf.2014.09.006.Peer-Reviewed Original ResearchConceptsPrimary prevention implantable cardioverter defibrillatorsImplantable cardioverter defibrillatorHeart failureCardioverter defibrillatorOlder womenNational Cardiovascular Data Registry ICD RegistryLeft ventricular dysfunctionSignificant survival benefitSurvival of womenYears of ageMedicare claims databaseEligible patientsCause mortalityPrimary endpointVentricular dysfunctionSurvival benefitICD RegistryClaims databaseHeart failure databaseLonger survivalClinical trialsPropensity score methodsPatientsWomenSurvival
2013
QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy
Peterson PN, Greiner MA, Qualls LG, Al-Khatib SM, Curtis JP, Fonarow GC, Hammill SC, Heidenreich PA, Hammill BG, Piccini JP, Hernandez AF, Curtis LH, Masoudi FA. QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. JAMA 2013, 310: 617-626. PMID: 23942680, DOI: 10.1001/jama.2013.8641.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBundle-Branch BlockCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesCardiovascular DiseasesCohort StudiesElectrocardiographyFee-for-Service PlansFemaleHeart FailureHumansMaleMedicarePatient ReadmissionRetrospective StudiesRiskTreatment OutcomeUnited StatesConceptsLeft bundle branch blockCRT-D implantationCardiac resynchronization therapyHeart failure readmissionQRS durationCause mortalityICD RegistryResynchronization therapyUnadjusted ratesMedicare beneficiariesNational Cardiovascular Data Registry ICD RegistryClinical practiceBundle branch block morphologyCause readmission rateRetrospective cohort studyLonger QRS durationBundle branch blockService Medicare beneficiariesCause readmissionCohort studyCRT-defibrillatorOlder patientsReadmission ratesHeart failureClinical trials
2005
Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project
Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, Havranek EP, Krumholz HM. Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project. JAMA Internal Medicine 2005, 165: 2237-2244. PMID: 16246989, DOI: 10.1001/archinte.165.19.2237.Peer-Reviewed Original ResearchConceptsHeart failureLower hematocrit levelsIndependent predictorsHematocrit levelsComorbid illnessesHigh riskCare ProjectMultivariable logistic regression analysisPatients 65 yearsPrincipal discharge diagnosisAcute care hospitalsLogistic regression analysisLow hematocrit valuesCause mortalityHF patientsMultiple comorbiditiesMultivariable adjustmentOlder patientsCare hospitalClinical factorsHospital readmissionComorbid conditionsDischarge diagnosisSevere anemiaAdverse outcomes
2004
Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials
Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials. JAMA Internal Medicine 2004, 164: 1389-1394. PMID: 15249347, DOI: 10.1001/archinte.164.13.1389.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedBisoprololBradycardiaCarbazolesCarvedilolDizzinessFatigueFemaleFollow-Up StudiesHeart Conduction SystemHeart FailureHumansHypotensionMaleMetoprololMiddle AgedPropanolaminesRisk FactorsRisk Reduction BehaviorSeverity of Illness IndexStatistics as TopicTreatment FailureVentricular Dysfunction, LeftWithholding TreatmentConceptsBeta-blocker therapyHeart failureAdverse effectsLeft ventricular systolic dysfunctionBeta-blocker trialsCardiovascular adverse effectsChronic heart failureHeart Failure TrialVentricular systolic dysfunctionΒ-blocker therapyRisk of hypotensionLife-saving therapyRandom-effects modelHF hospitalizationCause mortalitySystolic dysfunctionCause withdrawalsFailure TrialRandomized trialsAbsolute riskElectronic searchPatientsMEDLINE databaseTherapyAbsolute increaseThe association of 6-minute walk performance and outcomes in stable outpatients with heart failure
Curtis J, Rathore S, Wang Y, Krumholz H. The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. Journal Of Cardiac Failure 2004, 10: 9-14. DOI: 10.1016/j.cardfail.2003.08.010.Peer-Reviewed Original ResearchHeart failureWalk testStable outpatientsDigitalis Investigation Group trialRisk of deathCause mortalityIdentifies patientsMultivariable analysisPrognostic valuePrognostic informationGroup trialsWalk performancePatientsTest distanceMortalityDeathOutpatientsOutcomesFailureAssociationBackgroundWeTrialsMonthsThe association of 6-minute walk performance and outcomes in stable outpatients with heart failure.
Curtis JP, Rathore SS, Wang Y, Krumholz HM. The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. Journal Of Cardiac Failure 2004, 10: 9-14. PMID: 14966769, DOI: 10.1016/s1071-9164(03)00705-x.Peer-Reviewed Original Research
2003
Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure. JAMA 2003, 289: 871-878. PMID: 12588271, DOI: 10.1001/jama.289.7.871.Peer-Reviewed Original ResearchConceptsSerum digoxin concentrationHigh serum digoxin concentrationsLeft ventricular ejection fractionVentricular ejection fractionHeart failureMortality rateDIG trialDigoxin therapyEjection fractionDigoxin concentrationsDepressed left ventricular systolic functionDigitalis Investigation Group trialHigher absolute mortality rateLeft ventricular systolic functionOverall mortality benefitVentricular systolic functionCause mortality ratesAbsolute mortality ratesLower mortality rateCause mortalityMultivariable adjustmentMortality benefitSystolic functionClinical outcomesSerum concentrations